Carl Regillo, MD: Advantages of Brolucizumab


It is highly likely to influence patient
compliance in a favorable way. Right now, it’s not that patients choose not to come back — that may happen but it’s usually a delay. They may be scheduled
8 weeks out but it may turn into 9 or 10 weeks out. It could be a
snowstorm, could be an illness that you were in the hospital. If that happens
over and over and over then they’re likely to lose the vision gains that we
get early on. It’s likely to compromise the long-term vision outcomes, but with
something that’s more durable you’ve got a little more latitude in terms of the
treatment interval. So, it’s not only about extending it but it’s also having
that flexibility in terms of when they really do for the next treatment. See, in
practice, we do a treat an extend approach with these anti-VEGF and
we’re going to continue to use the new drugs that are likely to be FDA approved
soon in the same fashion. Each patient has a different treatment interval
based on their specific needs and in practice with our current therapeutics
that range of treatment intervals is between 4 and 12 weeks and then
we sort of arbitrarily cap it at 12 weeks but studies do show that not many
people can go beyond 12 weeks about a third of patients can go 12 weeks with
our current drugs. This has the potential to have a half the patients go 12 weeks.
So, you’re shifting that distribution to sort of the mean and median is shifting
towards something longer and the range and we might now be
looking at 8 to 16 weeks or 8 to 14 weeks and that’s meaningful — that’s very
meaningful for our patients. If you were getting injections 6 or 8 times a
year and I told you you can get 1 or 2 less treatments and 1 or 2 less
visits great. That’s meaningful for patients

Add a Comment

Your email address will not be published. Required fields are marked *